Stockscreener 앱 받기
1.68
4.35%
0.07
시간 외 거래:
1.72
0.04
+2.38%
Cardiff Oncology Inc 주식(CRDF)의 최신 뉴스
MSN Money - MSN
CRDF Technical Analysis & Stock Price Forecast - Intellectia AI
CRDF Q1'26 Earnings: EPS estimate is (0.13) USD - TradingView
[Form 4] Cardiff Oncology, Inc. Insider Trading Activity - Stock Titan
Cardiff Oncology (CRDF) COO Ajay Aggarwal submits initial insider ownership - Stock Titan
New Cardiff Oncology COO gets 400,000 stock options at $1.72 - Stock Titan
CRDF SEC FilingsCardiff Oncology Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Cardiff Oncology appoints Mani Mohindru as CEO - MSN
Cardiff Oncology Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Mayo Clinic leukemia expert joins Cardiff webinar on CMML drug data - Stock Titan
Cardiff Oncology (CRDF) price target decreased by 17.38% to 8.74 - MSN
Cardiff Oncology slumps after leadership shakeup - MSN
[ARS] Cardiff Oncology, Inc. SEC Filing - Stock Titan
[DEF 14A] Cardiff Oncology, Inc. Definitive Proxy Statement - Stock Titan
CRDF Q1'26 Earnings: revenue estimate is 88.57K USD - TradingView
CRDF (Cardiff Oncology Inc.) reports narrower than expected Q4 2025 loss, shares climb 4.29% on positive investor sentiment.Buyback Report - Cổng thông tin điện tử tỉnh Lào Cai
Cardiff Oncology to present colorectal cancer trial data at ASCO By Investing.com - Investing.com India
Cardiff Oncology to present colorectal cancer trial data at ASCO - Investing.com
Cardiff Oncology to Present Updated Data on Onvansertib in RAS-Mutated Colorectal Cancer at ASCO 2026 - Quiver Quantitative
Updated metastatic colon cancer data gets ASCO oral slot - Stock Titan
Cardiff Oncology, Inc. (NASDAQ:CRDF) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
H.C. Wainwright reiterates Cardiff Oncology stock rating at buy By Investing.com - Investing.com Canada
Cardiff Oncology Presents Preclinical Data on its PLK1 Inhibitor Onvansertib in Combination with a HER2-Targeted ADC at the 2026 AACR Annual Meeting - Sahm
Cardiff Oncology presents preclinical data on cancer drug combo By Investing.com - Investing.com India
Cardiff Oncology (CRDF) Unveils Promising Preclinical Data at AA - GuruFocus
Cardiff Oncology presents preclinical data on cancer drug combo - Investing.com
Cardiff Oncology (CRDF) CFO discloses initial holding of 500 common shares - Stock Titan
Cardiff Oncology (NASDAQ: CRDF) CFO awarded 486,650 stock options - Stock Titan
Cardiff Oncology (CRDF) CSO granted 300,000 stock options expiring 2036 - Stock Titan
Cardiff Oncology (CRDF) CFO receives 486,650 options at $1.58 strike - Stock Titan
Momentum Shift: Is Cardiff Oncology Inc likely to announce a buyback2026 Breakouts & Breakdowns & Smart Swing Trading Techniques - baoquankhu1.vn
Cardiff Oncology Appoints Mani Mohindru as CEO and Expands Executive Team to Advance Cancer Drug Onvansertib - Minichart
Cardiff Oncology announces key leadership appointments to strengthen executive team for next phase of growth - marketscreener.com
Cardiff Oncology Announces Key Leadership Appointments to Strengthen Executive Team for Next Phase of Growth - Bitget
Cardiff Oncology, Inc. Announces Management Appointments - marketscreener.com
Cardiff Oncology (CRDF) Appoints New Leadership Team - GuruFocus
Cardiff Oncology, Inc. Appoints Josh Muntner as Chief Financial Officer, Effective April 6, 2026 - marketscreener.com
Cardiff Oncology, Inc. Appoints Mani Mohindru as Chief Executive Officer - marketscreener.com
Cardiff Oncology appoints new CEO, CFO and COO - TipRanks
Form 8-KCurrent report - ADVFN
1.77%
0.25%
자본화:
|
볼륨(24시간):